MCID: NRL004
MIFTS: 43

Neuroleptic Malignant Syndrome

Categories: Blood diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neuroleptic Malignant Syndrome

MalaCards integrated aliases for Neuroleptic Malignant Syndrome:

Name: Neuroleptic Malignant Syndrome 12 76 53 54 59 37 55 44 15 73

Characteristics:

Orphanet epidemiological data:

59
neuroleptic malignant syndrome
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:14464
ICD10 33 G21.0
ICD9CM 35 333.92
MeSH 44 D009459
NCIt 50 C94829
SNOMED-CT 68 15244003 68977009
Orphanet 59 ORPHA94093
MESH via Orphanet 45 D009459
UMLS via Orphanet 74 C0027849
ICD10 via Orphanet 34 G21.0
KEGG 37 H01528
UMLS 73 C0027849

Summaries for Neuroleptic Malignant Syndrome

NIH Rare Diseases : 53 Neuroleptic malignant syndrome is a rare neurological condition that is caused by an adverse reaction to neuroleptic (tranquilizer) or antipsychotic drugs. These drugs are commonly prescribed for the treatment of schizophrenia and other neurological, mental, or emotional disorders. Affected people may experience high fever, muscle stiffness, sweating, unstable blood pressure, altered mental status, and autonomic dysfunction. In most cases, the condition develops within the first 2 weeks of treatment with the drug; however, it may develop any time during the therapy period. The exact underlying cause of neuroleptic malignant syndrome is unknown. In some cases, more than one family member can be affected which suggests there may be a genetic component. Upon diagnosis of the condition, the neuroleptic or antipsychotic drug is generally discontinued under a physician's supervision. Medications and/or other interventions may also be recommended to manage symptoms.

MalaCards based summary : Neuroleptic Malignant Syndrome is related to serotonin syndrome and malignant hyperthermia. An important gene associated with Neuroleptic Malignant Syndrome is PIK3C2A (Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Alpha). The drugs Artemether and Lumefantrine have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A nervous system disease that is characterized by hyperthermia, muscular rigidity, autonomic dysfunction and altered consciousness and is associated with administration of antipsychotic and other central dopaminergic blockers.

NINDS : 54 Neuroleptic malignant syndrome is a life-threatening, neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. Symptoms include high fever, sweating, unstable blood pressure, stupor, muscular rigidity, and autonomic dysfunction. In most cases, the disorder develops within the first 2 weeks of treatment with the drug; however, the disorder may develop any time during the therapy period. The syndrome can also occur in people taking anti-Parkinsonism drugs known as dopaminergics if those drugs are discontinued abruptly.

Wikipedia : 76 Neuroleptic malignant syndrome (NMS) is a life-threatening reaction that can occur in response to... more...

Related Diseases for Neuroleptic Malignant Syndrome

Diseases related to Neuroleptic Malignant Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)
# Related Disease Score Top Affiliating Genes
1 serotonin syndrome 30.8 CYP2D6 HTR1A
2 malignant hyperthermia 30.6 MB PIK3C2A RYR1
3 disseminated intravascular coagulation 30.2 MB PIK3C2A
4 myoglobinuria 30.1 MB PIK3C2A
5 galactorrhea 30.0 CYP2D6 DRD2
6 plexopathy 29.9 MB PIK3C2A
7 muscle disorders 29.9 PIK3C2A RYR1
8 acute myocardial infarction 29.8 CHKB MB PIK3C2A
9 generalized anxiety disorder 29.7 DRD2 HTR1A
10 compartment syndrome 29.5 CHKB MB PIK3C2A
11 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 29.5 CHKB MB PIK3C2A RYR1
12 parkinson disease, late-onset 29.4 CYP2D6 DRD2 HTR1A
13 encephalitis 10.3
14 schizophrenia 10.2
15 dementia 10.2
16 virus associated hemophagocytic syndrome 10.2 MB PIK3C2A
17 interstitial myocarditis 10.2 MB PIK3C2A
18 posterior myocardial infarction 10.2 MB PIK3C2A
19 myositis fibrosa 10.2 MB PIK3C2A
20 gas gangrene 10.2 MB PIK3C2A
21 anuria 10.1 MB PIK3C2A
22 delusional disorder 10.1 CYP2D6 DRD2
23 intermediate coronary syndrome 10.1 MB PIK3C2A
24 tardive dyskinesia 10.1 CYP2D6 DRD2
25 pseudohyperkalemia, familial, 2, due to red cell leak 10.1 MB PIK3C2A
26 brain injury 10.1
27 status epilepticus 10.1
28 dystonia 10.1
29 encephalopathy 10.1
30 acute mountain sickness 10.1 MB PIK3C2A
31 gastroparesis 10.1 CYP2D6 DRD2
32 acute kidney failure 10.1 MB PIK3C2A
33 myocardial infarction 10.1
34 rigidity and multifocal seizure syndrome, lethal neonatal 10.1
35 bipolar disorder 10.1
36 cerebral palsy 10.1
37 thrombocytopenia 10.1
38 traumatic brain injury 10.1
39 cocaine abuse 10.1
40 cerebellar degeneration 10.1
41 substance-induced psychosis 10.0 DRD2 HTR1A
42 social phobia 10.0 DRD2 HTR1A
43 periodic limb movement disorder 10.0 DRD2 HTR1A
44 drug-induced mental disorder 10.0 DRD2 HTR1A
45 drug psychosis 10.0 DRD2 HTR1A
46 alexithymia 10.0 DRD2 HTR1A
47 mental depression 10.0 CYP2D6 HTR1A
48 migraine without aura 10.0 DRD2 HTR1A
49 substance abuse 10.0 CYP2D6 DRD2
50 muscle tissue disease 10.0 MB PIK3C2A RYR1

Graphical network of the top 20 diseases related to Neuroleptic Malignant Syndrome:



Diseases related to Neuroleptic Malignant Syndrome

Symptoms & Phenotypes for Neuroleptic Malignant Syndrome

MGI Mouse Phenotypes related to Neuroleptic Malignant Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.63 CHKB DRD2 HTR1A NHLRC1 PIK3C2A RYR1
2 homeostasis/metabolism MP:0005376 9.5 CHKB DRD2 HTR1A MB NHLRC1 PIK3C2A
3 muscle MP:0005369 9.02 CHKB DRD2 MB NHLRC1 RYR1

Drugs & Therapeutics for Neuroleptic Malignant Syndrome

Drugs for Neuroleptic Malignant Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Artemether Approved Phase 4 71963-77-4 119380 68911
2
Lumefantrine Approved Phase 4 82186-77-4 6437380
3
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
4
Haloperidol Approved Phase 4,Phase 3,Phase 2 52-86-8 3559
5
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
6 Antipsychotic Agents Phase 4,Phase 3,Phase 2
7 Antiparasitic Agents Phase 4
8 Antimalarials Phase 4
9 Artemether-lumefantrine combination Phase 4
10 Anti-Infective Agents Phase 4,Phase 2
11 Antiprotozoal Agents Phase 4
12 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Psychotropic Drugs Phase 4,Phase 3,Phase 2
14 decanoic acid Phase 4,Phase 3,Phase 2
15 Dopamine Antagonists Phase 4,Phase 3,Phase 2
16 Haloperidol decanoate Phase 4,Phase 3,Phase 2
17 Antiemetics Phase 4,Phase 3,Phase 2
18 Dopamine Agents Phase 4,Phase 3,Phase 2
19 Tranquilizing Agents Phase 4,Phase 3,Phase 2
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
24 Cholinergic Agents Phase 4,Not Applicable
25 Central Nervous System Stimulants Phase 4,Not Applicable
26 Cholinergic Antagonists Phase 4
27 Solifenacin succinate Phase 4 242478-38-2
28 Muscarinic Antagonists Phase 4
29 Dopamine Uptake Inhibitors Phase 4
30 Neurotransmitter Uptake Inhibitors Phase 4
31
Levodopa Approved Phase 3 59-92-7 6047
32
Carbidopa Approved Phase 3 28860-95-9 34359 38101
33
Ziprasidone Approved Phase 3 146939-27-7 60854
34 Quetiapine Fumarate Phase 3 111974-72-2
35 Immunologic Factors Phase 3,Phase 1
36 Dopamine agonists Phase 3
37 Adjuvants, Immunologic Phase 3
38 Aromatic Amino Acid Decarboxylase Inhibitors Phase 3
39 Antiparkinson Agents Phase 3
40 Carbidopa, levodopa drug combination Phase 3
41 Serotonin Antagonists Phase 3
42 Serotonin Agents Phase 3
43
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
44
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
45
Exenatide Approved, Investigational Phase 2 141758-74-9 15991534
46
Ethanol Approved Phase 2 64-17-5 702
47
Lenvatinib Approved, Investigational Phase 2 417716-92-8
48
Midazolam Approved, Illicit Phase 2 59467-70-8 4192
49
Ketamine Approved, Vet_approved Phase 2 6740-88-1 3821
50
Testosterone Approved, Investigational Phase 2 58-22-0 6013

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Impact of Enhanced Health Facility Care in Uganda Completed NCT01024426 Phase 4
2 Agents Intervening Against Delirium in Intensive Care Unit Recruiting NCT03392376 Phase 4 Haloperidol Injection
3 Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome Active, not recruiting NCT03468465 Phase 4 Solifenacin Succinate
4 The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease. Terminated NCT01244269 Phase 4 Methylphenidate;Methylphenidate;Placebo 10;Placebo 20
5 Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium Completed NCT01811459 Phase 3 Quetiapine;Haloperidol;Placebo
6 Nabilone for Non-motor Symptoms in Parkinson's Disease Recruiting NCT03773796 Phase 3 Nabilone 0.25 mg
7 A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) Recruiting NCT02549092 Phase 3 ABT-SLV187
8 The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study Active, not recruiting NCT01211522 Phase 3 Haloperidol;Ziprasidone;Placebo
9 Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial Unknown status NCT01627132 Phase 2 Dasatinib
10 Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study Unknown status NCT01174810 Phase 2 Exenatide
11 Mindfulness Based Intervention (MBI) on the Quality of Life and Non-Motor Symptoms (NMS) of Persons With PD Completed NCT01607697 Phase 2
12 Neuromuscular Magnetic Stimulation in ALS Patients Completed NCT03618966 Phase 2
13 Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia Completed NCT01176721 Phase 2
14 Nucleus Basalis Deep Brain Stimulation for Thinking & Memory Problems in Parkinson's. Completed NCT01701544 Phase 1, Phase 2
15 Nabilone for Non-motor Symptoms in Parkinson's Disease Recruiting NCT03769896 Phase 2 Nabilone 0.25 mg;Placebo
16 Influence of Beer on Gut Microbiota and Biochemical Outcomes: Alcohol Impact. Recruiting NCT03513432 Phase 2
17 Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer Recruiting NCT02726503 Phase 2 Lenvatinib
18 Rapid Agitation Control With Ketamine in the Emergency Department Recruiting NCT03375671 Phase 2 Ketalar;Midazolam injection;Haloperidol
19 Identification of a Biomarker Predictive of Evolution of Parkinson Disease Recruiting NCT03230526 Phase 2 [18F]DPA-714 PET scan
20 Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture. Recruiting NCT03545347 Phase 2 Nandrolone Decanoate;Sodium Chloride 9mg/ml Injection
21 A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease Recruiting NCT03582137 Phase 2 Cannabidiol
22 Recovery of Physical Functioning After Hip Fracture Unknown status NCT02780076 Phase 1
23 Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors Completed NCT01014429 Phase 1 NMS-1286937
24 Safety of RG2077 in Patients With Multiple Sclerosis Completed NCT00076934 Phase 1 RG2077 (CTLA4-IgG4m)
25 Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity Completed NCT02216188 Phase 1
26 Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA) Completed NCT02618941 Phase 1
27 Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients Active, not recruiting NCT02854683 Phase 1 Normal Saline
28 Study of the Fecal Microbiome in Patients With Parkinson's Disease Not yet recruiting NCT03671785 Phase 1 PRIM-DJ2727;Placebo oral capsule
29 Study of NMS-1116354 in Solid Tumors Terminated NCT01016327 Phase 1 NMS-1116354
30 Study of NMS-1116354 in Advanced/Metastatic Solid Tumors Terminated NCT01092052 Phase 1 NMS-1116354
31 Occipital Nerve Stimulation in the Treatment of Migraine Terminated NCT01855672 Phase 1
32 Neuromuscular Electrostimulation in Radiocephalic Fistula Unknown status NCT02925845 Not Applicable
33 The Iliac Arterio-venous Fistula for Treatment of Neurally Mediated Syncope Study Unknown status NCT02388087 Not Applicable
34 Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients Unknown status NCT01022450
35 Understanding and Appraising the New Medicine Service in England Completed NCT01635361 Not Applicable
36 Incidence of Residual Neuromuscular Blockade in Intra-abdominal Surgery: A Prospective, Observational Study Completed NCT02984839
37 Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With Rotigotine Completed NCT01504529
38 Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307) Completed NCT01495741
39 Help-seeking for Health Problems in People With Parkinson's Completed NCT03275649
40 A Feasibility Study of the Impact on Blood Pressure Control of Supplementing Community Pharmacist Services With Structured Information on Blood Pressure and Its Treatment Completed NCT01939860 Not Applicable
41 Distribution of Non-Motor Symptoms in Idiopathic Parkinson's Disease and Secondary Parkinsonism Completed NCT03432338
42 Incidence of Postoperative Neuromuscular Blockade in Post-Anesthesia Care Unit at Parkland Hospital: Does Size Matter? Completed NCT03111082
43 Long Time Follow up After HJ Following Iatrogenic Bile Duct Injuries Completed NCT01447030
44 Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks. Completed NCT01702259 Not Applicable
45 Postoperative Blood Transfusion for Frail Elderly With Hip Fracture Completed NCT01102010 Early Phase 1
46 rTMS Effects on Smoking Cessation and Cognition in Schizophrenia Completed NCT00736710 Not Applicable
47 Effects of Green Light Therapy on Body Contouring and Cellulite Completed NCT03647748 Not Applicable
48 Functional Performance Following Emergency High-risk Abdominal Surgery Completed NCT02124356
49 Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults Completed NCT03761979 Not Applicable
50 Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy Completed NCT02734485 Not Applicable

Search NIH Clinical Center for Neuroleptic Malignant Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: neuroleptic malignant syndrome

Genetic Tests for Neuroleptic Malignant Syndrome

Anatomical Context for Neuroleptic Malignant Syndrome

MalaCards organs/tissues related to Neuroleptic Malignant Syndrome:

41
Kidney, Heart, Brain, Liver, Lung, Tongue, Thyroid

Publications for Neuroleptic Malignant Syndrome

Articles related to Neuroleptic Malignant Syndrome:

(show top 50) (show all 1035)
# Title Authors Year
1
Reversible splenial lesion in neuroleptic malignant syndrome. ( 29696960 )
2018
2
Neuroleptic Malignant Syndrome ( 29489248 )
2018
3
Neuroleptic malignant syndrome: a case responding to electroconvulsive therapy plus bupropion. ( 29441189 )
2018
4
Neuroleptic Malignant Syndrome: Diagnosis and Management. ( 29325237 )
2018
5
Neuroleptic malignant syndrome in pregnancy: case report and literature review. ( 29363376 )
2018
6
Olanzapine as a cause of neuroleptic malignant syndrome, bibliographic review following a clinical case. ( 29892970 )
2018
7
Serotonin syndrome versus neuroleptic malignant syndrome: a case report. ( 29616715 )
2018
8
A Mixed Presentation of Serotonin Syndrome vs Neuroleptic Malignant Syndrome in a 12-Year-Old Boy. ( 29698346 )
2018
9
Neuroleptic malignant syndrome as a presenting feature of subacute sclerosing panencephalitis. ( 29243130 )
2018
10
Dantrolene for Treatment of Suspected Neuroleptic Malignant Syndrome. ( 29548378 )
2018
11
Case report of neuroleptic malignant syndrome with prolonged mental changes and severe dyskinesia. ( 29464897 )
2018
12
Toxic Myopathy due to Antidopaminergic Medication Without Neuroleptic Malignant Syndrome. ( 30439755 )
2018
13
A Neuroleptic Malignant Syndrome Without Rigidity. ( 29475219 )
2018
14
Diagnostic, Treatment, and System Challenges in the Management of Recurrent Neuroleptic Malignant Syndrome on a General Medical Service. ( 29992074 )
2018
15
Neuroleptic malignant syndrome following reintroduction of an antipsychotic after overdose. ( 30076161 )
2018
16
Neuroleptic Malignant Syndrome: The Value of Diagnostic Criteria. ( 30085440 )
2018
17
Forced Diuresis and Expedient Blood Pressure Control in the Management of Quetiapine Induced Neuroleptic Malignant Syndrome: A Case Report. ( 30087734 )
2018
18
Levosulpiride-induced neuroleptic malignant syndrome in rheumatoid arthritis. ( 30100569 )
2018
19
A Case of Neuroleptic Malignant Syndrome in a Profoundly Intellectually Disabled Patient with Successful Reintroduction of Antipsychotic Therapy with Quetiapine. ( 30112240 )
2018
20
Atypical Neuroleptic Malignant Syndrome Precipitated by Clozapine and Quetiapine Overdose: A Diagnostic Challenge. ( 30254795 )
2018
21
Acute Abdomen with Ileus: A Heralding Presentation of Neuroleptic Malignant Syndrome. ( 30323731 )
2018
22
Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. ( 30375086 )
2018
23
Pharmacist-Initiated Management of a Suspected Case of Risperidone-Induced Neuroleptic Malignant Syndrome in an Aged-Care Resident. The Role of Residential Medication Management Reviews in Medication Safety. ( 30428759 )
2018
24
Neuroleptic malignant syndrome in a patient treated with clotiapine. ( 30439816 )
2018
25
Psoas Abscess as a Differential Diagnosis of Neuroleptic Malignant Syndrome in a Schizoaffective Disorder Patient With Catatonic Symptoms. ( 30444963 )
2018
26
Neuroleptic malignant syndrome and serotonin syndrome. ( 30459031 )
2018
27
Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015. ( 30506147 )
2018
28
Neuroleptic malignant syndrome with thyroid disorder: An unusual case report. ( 28953679 )
2017
29
Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. ( 28144147 )
2017
30
Lurasidone-Associated Neuroleptic Malignant Syndrome. ( 28806387 )
2017
31
Early introduction of clozapine after neuroleptic malignant syndrome may prevent malignant catatonia: A case report. ( 27939254 )
2017
32
Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association. ( 28811916 )
2017
33
Risperidone-Associated Rhabdomyolysis Without Neuroleptic Malignant Syndrome: A Case Report. ( 27861195 )
2017
34
Neuroleptic malignant syndrome in the trauma intensive care unit: Diagnosis and management of a rare disease in a challenging population. ( 28660166 )
2017
35
Confusing Terminology-Neuroleptic Malignant Syndrome vs Malignant Hyperthermia. ( 28558090 )
2017
36
Neuroleptic malignant syndrome following catatonia: Vigilance is the price of antipsychotic prescription. ( 28491312 )
2017
37
A Case of "Brief" Aripiprazole-induced Neuroleptic Malignant Syndrome with Symptoms that Only Lasted a Few Hours. ( 28943586 )
2017
38
Neuroleptic Malignant Syndrome/Malignant Catatonia in Child Psychiatry: Literature Review and a Case Series. ( 28398818 )
2017
39
A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. ( 28027111 )
2017
40
Neuroleptic malignant syndrome associated with only one dose of metoclopramide in an older adult. ( 28849625 )
2017
41
Pharmacist intervention to detect drug adverse events on admission to the emergency department: Two case reports of neuroleptic malignant syndrome. ( 28488314 )
2017
42
A retrospective analysis of cases with neuroleptic malignant syndrome and an evaluation of risk factors for mortality. ( 29464217 )
2017
43
Early detection of an atypical presentation of neuroleptic malignant syndrome: A case report. ( 29955512 )
2017
44
Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Risk of Neuroleptic Malignant Syndrome. ( 27836566 )
2017
45
Neuroleptic Malignant Syndrome After Early Administration of Risperidone Long-Acting Injection. ( 29195036 )
2017
46
Neuroleptic malignant syndrome in a patient with stable dose of olanzapine. ( 29026773 )
2017
47
Olanzapine-Induced Neuroleptic Malignant Syndrome. ( 28533580 )
2017
48
Managing Manic Delirium in Bipolar Disorder With Features of Mania, Catatonia, and Neuroleptic Malignant Syndrome. ( 29272572 )
2017
49
Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management. ( 29061403 )
2017
50
Neuroleptic malignant syndrome following quetiapine treatment in a patient with dementia with Lewy bodies. ( 29080512 )
2017

Variations for Neuroleptic Malignant Syndrome

Expression for Neuroleptic Malignant Syndrome

Search GEO for disease gene expression data for Neuroleptic Malignant Syndrome.

Pathways for Neuroleptic Malignant Syndrome

GO Terms for Neuroleptic Malignant Syndrome

Biological processes related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 release of sequestered calcium ion into cytosol GO:0051209 8.96 DRD2 RYR1
2 response to hypoxia GO:0001666 8.8 DRD2 MB RYR1

Molecular functions related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 8.62 CYP2D6 DRD2

Sources for Neuroleptic Malignant Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....